Mount Sinai Health System Launches Center for Psychedelic Research
Psychedelic Finance, January 8, 2021
The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multi-pronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.
Why Investors Are Psyched About Psychedelic Stocks
Visual Capitalist, January 7, 2021
Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.
Health care professionals okayed to use magic mushrooms for training in psilocybin therapy
Now Toronto, December 9, 2020
Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.
Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.
The Age, December 8, 2020
Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.
Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s
Parkinson's News Today, December 4, 2020
Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.
United Nations approves WHO recommendation to reschedule cannabis in historic vote
Marijuana Business Daily, December 2, 2020
The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
Jewish psychedelics advocate working to turn drug into legal medicine
The Jerusalem Post, November 20, 2020
In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.
‘The war on drugs failed’: California lawmaker will push to decriminalise psychedelics
The Guardian, November 20, 2020
A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.
Psilocybin for Depression Study Approved and Funded by German Government
Psilocybin Alpha, November 19, 2020
The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.
Canada Is Allowing People With Depression to Do Psychedelic Mushrooms
Vice World News, November 17, 2020
The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.
What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD
The Dales Report, November 11, 2020
The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.
Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’
CNBC, November 4, 2020
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
Washington, DC, just decriminalized psychedelic plants. Here’s what happens next
Leafly, November 4, 2020
Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.
Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020)
Ballotpedia, November 3, 2020
Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved.
Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms
Forbes, October 23, 2020
A Vancouver-based psychedelics company has become the first in Canada to complete a legal harvest of magic mushrooms since the last wave of psychedelic research ended there in the 1970s.
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MAPS, October 14, 2020
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
Plos One, October 14, 2020
Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs. Treatment options are limited. A novel therapy using 3,4-methylenedioxymethamphetamine (MDMA) has shown efficacy in six phase 2 trials. Its cost-effectiveness is unknown.
Are psychedelics the answer to depression and addiction?
Salon, April 22, 2018
A new generation of research into psilocybin could change how we treat numerous mental health conditions.